Literature DB >> 26001143

Mediastinal nodal involvement in patients with clinical stage I non-small-cell lung cancer: possibility of rational lymph node dissection.

Tomohiro Haruki1, Keiju Aokage, Tomohiro Miyoshi, Tomoyuki Hishida, Genichiro Ishii, Junji Yoshida, Masahiro Tsuboi, Hiroshige Nakamura, Kanji Nagai.   

Abstract

BACKGROUND: The aim of this study is to elucidate the optimal candidate of selective lymph node dissection (LND) that reduces the extent of mediastinal LND according to clinical information including radiological evaluation in primary non-small-cell lung cancer (NSCLC) patients.
METHODS: Eight hundred and seventy-six patients with clinical(c)-stage I NSCLC (adenocarcinoma and squamous cell carcinoma), who underwent complete surgical resection between January 2003 and December 2009 were included in this study. We elucidated the lymph node metastatic incidence and distribution according to the primary tumor lobe location and extracted the associated clinicopathological factors, especially thin-section computed tomographic findings, with mediastinal lymph node involvement.
RESULTS: The total incidence of mediastinal lymph node metastasis was 9.1%. There were no cases with hilar and mediastinal lymph node metastasis in ground glass opacity-predominant tumors. There was no significant association of clinical factors with subcarinal lymph node metastasis in right upper-lobe and left upper-division adenocarcinoma. An elevated preoperative serum carcinoembryonic antigen level (p < 0.001) showed significant associations with upper mediastinal lymph node metastasis in the patients with bilateral lower-lobe primary lung adenocarcinoma.
CONCLUSIONS: It would be acceptable to perform selective LND in patients with c-stage I NSCLC with ground glass opacity- predominant tumor. Elevated serum carcinoembryonic antigen was associated with upper mediastinal lymph node involvement in lower-lobe primary lung adenocarcinoma with radiologically solid-predominant tumor. We should be careful when applying selective LND to patients with solid-predominant tumor, especially located in the lower lobe.

Entities:  

Mesh:

Year:  2015        PMID: 26001143     DOI: 10.1097/JTO.0000000000000546

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  32 in total

1.  Early stage lung cancer with nodal involvement occult to PET-CT: treat the image or treat the disease?

Authors:  Janusz Kowalewski; Mariusz Kowalewski; Paweł Wnuk
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.

Authors:  Youngkyu Moon; Kyo Young Lee; Kyung Soo Kim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  From anatomy to lung cancer: questioning lobe-specific mediastinal lymphadenectomy reliability.

Authors:  Marc Riquet; Ciprian Pricopi; Alex Arame; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor.

Authors:  Youngkyu Moon; Sook Whan Sung; Min Namkoong; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

5.  Mediastinal lymph node resection in stage IA non-small cell lung cancer with small nodule: is it mandatory?

Authors:  Dong Kwan Kim
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

6.  Occult pN2 disease in lung cancer patients: a wide range of diseases endangering the long term prognosis.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 7.  Selective lymph node dissection in early-stage non-small cell lung cancer.

Authors:  Han Han; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

8.  Surgery for mediastinal lymph node and early stage lung cancer: individualized practice based on clinical database.

Authors:  Yi-Ting Yen; Yau-Lin Tseng
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Should a therapeutic strategy be based on how the disease was diagnosed?

Authors:  Masaaki Sato
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

10.  Prognosis after wedge resection in patients with 8th edition TNM stage IA1 and IA2 non-small cell lung cancer.

Authors:  Youngkyu Moon; Jae Kil Park; Kyo Young Lee; Eun Sung Kim
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.